The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
By Douglas G. Altman, K. F. Schulz, David Moher, Matthias Egger, Frank Davidoff, Diana Elbourne, Peter Gtzsche, Thomas Lang. Annals of Internal Medicine, 2001
3,977 citations recorded by the source corpus.
Subfields: Economics and Econometrics, Statistics and Probability
View Paper: https://www.semanticscholar.org/paper/8dc46602dd3e5e8d0991f5267ad438e2fbf1eb10
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
- Douglas G. Altman
- David Moher
- K. F. Schulz
- Gary S. Collins
- Karel G. M. Moons
- Johannes B Reitsma
- Stanley E. Lazic
- Matthias Egger
In Statistics and Probability
- Douglas G. Altman
- David Moher
- K. F. Schulz
- Gary S. Collins
- Karel G. M. Moons
- Johannes B Reitsma
- Matthias Egger
- Peter C. Austin
Citations in the corpus
- Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. (2006, background): “This is a randomized, controlled, open intervention trial involving patients with all severities of CAP admitted to the emergency department (27).”
- Imputing missing standard deviations in meta-analyses can provide accurate results. (2006, background): “The recent consorted efforts by journal editors and clinical epidemiologists to call for better reporting of trial findings represent a step forward to remedy this situation [15].”
- Sample size determination and power analysis using the G*Power software (2021, background): “Although there have been debates on sample size calculation and power analysis [3,4,6], the need for an appropriate sample size calculation has become a major trend in research [1,2,7-11].”
- Effectiveness of school-based programs to reduce bullying: a systematic and meta-analytic review (2011, background): “Future reports should provide key information about features of evaluations, according to a checklist that should be developed, inspired perhaps by the CONSORT Statement for medical research (see Altman et al. 2001; Moher et al. 2001; Perry and Johnson 2008).”
- REporting recommendations for tumour MARKer prognostic studies (REMARK) (2005, methodology): “As noted, a detailed explanatory paper is in preparation, following the model of similar articles relating to the CONSORT and STARD statements (Altman et al, 2001; Bossuyt et al, 2003b).”
- Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. (2004, neutral): “Study design Parallel-group 70 (69) Crossover 30 (29) Other* 2 (2) Intervention Drug 77 (75) Surgery/procedure 11 (11) Counseling/lifestyle 12 (12) Equipment 2 (2) Study centers Single 53 (52) Multiple 49 (48) Funding Full industry 56 (55) Partial industry 17 (17) Nonindustry 22 (22) None declared 7”